Pharmacogenomic Analysis of Response to Topical Tumor Necrosis Factor α Antagonist Licaminlimab (OCS-02) in Dry Eye Disease: Retraction. (PubMed, Cornea) - Sep 3, 2024 - No abstract available
Biomarker • Journal • Dry Eye Disease • Oncology • Ophthalmology
|